Sagimet Biosciences Future Growth
Future criteria checks 2/6
Sagimet Biosciences's earnings are forecast to decline at 32.7% per annum while its annual revenue is expected to grow at 87.4% per year. EPS is expected to decline by 26.3% per annum. Return on equity is forecast to be -35.2% in 3 years.
Key information
-32.7%
Earnings growth rate
-26.3%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 87.4% |
| Future return on equity | -35.2% |
| Analyst coverage | Good |
| Last updated | 05 Dec 2024 |
Recent future growth updates
No updates
Recent updates
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Dec 15
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -197 | -214 | -206 | 6 |
| 12/31/2025 | 1 | -119 | -120 | -109 | 7 |
| 12/31/2024 | N/A | -50 | -46 | -33 | 6 |
| 9/30/2024 | N/A | -38 | -38 | -38 | N/A |
| 6/30/2024 | 2 | -29 | -23 | -23 | N/A |
| 3/31/2024 | 2 | -28 | -23 | -23 | N/A |
| 12/31/2023 | 2 | -28 | -24 | -24 | N/A |
| 9/30/2023 | 2 | -27 | -24 | -24 | N/A |
| 6/30/2023 | N/A | -28 | -26 | -26 | N/A |
| 3/31/2023 | N/A | -28 | -27 | -27 | N/A |
| 12/31/2022 | N/A | -30 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -24 | -22 | -22 | N/A |
| 12/31/2020 | N/A | -11 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGMT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SGMT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SGMT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SGMT's revenue (87.4% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: SGMT's revenue (87.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SGMT is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sagimet Biosciences Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrea Tan | Goldman Sachs |
| Andrea Newkirk | Goldman Sachs |
| Antonio Arce | H.C. Wainwright & Co. |